Rationale and design of ENDEAVOR: A sequential phase 2b–3 randomized clinical trial to evaluate the effect of myeloperoxidase inhibition on symptoms and exercise capacity in heart failure with preserved or mildly reduced ejection fraction. - Lund, Lars H.; Lam, Carolyn S.P.; Pizzato, Patricia E.; Gabrielsen, Anders; Michaëlsson, Erik; Nelander, Karin; Ericsson, Hans; Holden, Julie; Folkvaljon, Folke; Mattsson, Andrea; Collén, Anna; Aurell, Malin; et al. (European Journal of Heart Failure, 2023)